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Preface
Telomeres define and predict the fate of our cells, and are capable to direct the man-
ner of quality and the quantitative values in the specific biological and molecular 
events. Telomeres could be also named as ‘Frontiers in cells’
By looking at a carved tree, we realize the multifarious position of circles indica-
tive of its age. But, in human, it is rather more complicated and we are exposed to 
the multi-influential factors, cooperating with the telomere territory. Therefore, the 
phenotype, as a sole, could not reflect the real age of the apparently normal and 
healthy individuals. Such machinery is even more confusing in cancer patients.
Telomeres act as a ‘Bio-Polar System’ within the cells which could direct and 
govern further events in our body.
In programming, ‘telomeres begin and terminate the cellular life’. Telomeres 
make the history of cellular fate, health status, the manner, and future of all cell 
types which contain chromosomal territory. Telomeres act as guard, protect the 
cells and guarantee the flow of existence and quality of life.
Telomeres, manage and interact with many events for cancer-puzzling. Normal 
telomere, ‘announcer of life’. Abnormal telomeres, ‘trigger and predictor of age 
and cancer’. In tact telomeres, ‘end points of natural and health status’. Telomeres 
are tracer as predictor, and prognostic values in health and malignant conditions. 
Shorter telomeres direct aberrant function of telomerase and could act as two edged 
sward.
Remembering the pioneers who discovered the original facts in telomere and 
telomerase, seems to be essential; Alexei Olovnikov and Leonard Hayflick (early 
1970s) by paving the way, later on Elizabeth Blackburn, Carol Greider, and Jack 
Szostak (1975–1978) the winner of 2009 Nobel Prize, had discovered the key role 
of telomeres and the enzyme telomerase for the protection of chromosomes. The 
original work of Russian theorist Alexei Olovnikov during 1970–1973, is highly 
appreciated. As he defined the root of Greek words for telomeres (telos “end” and 
merοs “part”), it had been clarified that why the end parts of chromosomes are so 
critical for the cellular fate and life.
Telomeres are not isolated; they are cooperative and interact with the whole ma-
chinery of Cell Biology, Genetics, and environment. They affect other cellular and 
molecular behavior, and could be affected by many targets in the cellular territories.
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Moreover, stem cell is reflective of heterogeneity, and cancer stem cell is sign of 
evolution and valuable contributor to the cancer research. This paradigm together 
with telomere territory would pave the way in cancer research towards an innova-
tive therapeutic strategy in future.
Focusing on the current book, it was aimed to provide an educational and re-
search package, preferentially based on the data achieved from our original research 
projects. The paradigms of in vivo and in vitro assays, as the essential facts, were 
also included and highlighted within different chapters. By believing in cancer pa-
tients’ right and trusting the role of genetics and cell biology, this book is developed 
through a clinical focal point, i.e., telomerase, as a therapeutic and bio-marker in 
two chapters. Gradually, the structure of chapters focused on introducing an ap-
plicable and new strategy in detection of telomerase activity. Further, telomere was 
explored, and followed by presenting the interaction between telomere, methylation 
and nutrition.
Impact of cancer stem cell in different malignancies with special focus on breast 
cancer was also discussed. Finally, in closing highlights, the whole chapters of this 
book were thoroughly reviewed.
This book reflects a broad insight in which different domains of life, including 
eukaryotes, prokaryotes, at in vivo, in vitro, and human levels, and cooperatively 
within the chapters were discussed. It also shows that how variety of species in-
cluding model organisms, fungi including yeast, plants, animals, and human could 
interact with each other in the nature and share a common biological target, i.e., 
telomere. This is indicative of, (1) A global diversity and selection, and (2) They 
need to combat against hazards in our environment, producing by them, by relying 
on the cellular and molecular events and, (3) Struggling to survive, but in a healthy 
condition. This is a message to ‘take care about our environment’.
That was also my honor to invite, as much as possible, a group including the na-
tional and international contributors from different centers as well. I was keenly in-
terested in designing the subject of chapters by considering a complementary strat-
egy of relevant issues in the telomere territory. Upon the manner of developmental 
based the core concepts in provided chapters focus on:
Chapter 1, “Telomerase From aging to human cancers” provides a complemen-
tary basis to serve the scientific investigators with the recent advances of telomerase 
in human cancers and aging.
Chapter 2, “Telomerase: Basic and clinical approaches” provides the key aspects 
in telomerase. Specifically, discuss our data on, (1) Association between telomerase 
activity and hTR in primary breast cancer patients, and (2) By considering clinico-
pathological parameters, expression of hTR and hTERT in the same patients were 
also included in this chapter.
Chapter 3, “Detection of telomerase activity: A New Strategy for Detecting 
Low Activity of Telomerase” presents a progressive and essentials techniques for 
detecting the telomerase activity including the “Trap assay family”. In addition, to 
bypass limitation such as low activity of telomerase, a new strategy has been also 
provided in which our data is presented.
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Chapter 4, “Telomere, Regulation and Tumorigenesis” mainly, focus on the 
classic information on structure, interaction between telomeres and DNA damage 
response, gene expression; and regulation of telomeric chromatin. Mechanism of 
telomere maintenance and Telomere position effect is also provided. Finally, our 
data on “telomere and telomerase in brain tumors” is included in this chapter.
Chapter 5, “Novel hypothesis on telomere length: heterogenic targets as genom-
ics/ somatic diverse value in breast cancer and brain tumor” explores the genomic-
somatic scenario of telomere length which was initially begun in a group of our 
patients affected with primary breast cancer, by including the follow up study. In 
second step, the same model of study was conducted in the patients affected with 
primary brain tumors.
Chapter 6, “Telomere, Methylation and Nutrition” provides the most important 
facts regarding the impact of nutritional elements on telomere length, DNA meth-
ylation and cancer predisposition. By improving the routine diet composition, the 
process of aging and cancer could be somehow protected. Such plan would provide 
a positive impact on the longevity and health of next generations in our pedigrees. 
The final message would be ‘balancing the dietary elements’.
Chapter 7, “Cancer stem cell” provides basic Information on stem cells and 
cancer stem cells. Paradigm of gene- gene interactions and cooperation between 
telomeres and CD44 + /Cd24- marker are discussed. The final word emphasized on 
the translational impact of this marker ‘CSC is the key target for personalized breast 
cancer management.’
Mini chapter 8, “Closing highlights: Final statements at a glance” defines telo-
mere territory as a globalizing domain in genetics and cell biology, interacting with 
many molecular and cellular targets, which dictate our style of life. The new insight 
include personalized selection, and cancer family indices through which an appro-
priate approaches could be planned within specific pedigrees as cancer-prone fami-
lies. This avenue would facilitate to consider the personalized cancer management.
Finally, whatever we learn about cellular duties in our body, there are still many 
unmasked facts in telomere territory.
I would also like to gratitude the continuous cooperation of surgeons, nurses, 
the clinical supportive team, and patients in our projects, whose mutual endeavor is 
sincerely appreciated.
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